Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Karyopharm Therapeutics Inc., Sanofi Genzyme, and Oncopeptides, Inc.

State-of-the-Art Care in Relapsed/Refractory Multiple Myeloma: Novel Targets, Combinations, and Treatment Approaches

Release Date: January 15, 2021
Expiration Date: January 15, 2022

Activity Overview

State-of-the-Art Care in Relapsed/Refractory Multiple Myeloma: Novel Targets, Combinations, and Treatment Approaches is an online, on-demand virtual symposium, which brings together renowned experts in multiple myeloma (MM). In this educational program, these experts use didactic sessions, panel discussions, and case presentations to discuss the latest advancements in the field of MM. This activity will help health care professionals maintain a state-of-the-art clinical practice by providing updates on novel agents under investigation, recently approved agents, new combination approaches, and optimal sequencing strategies.

This educational activity is an archive of the live virtual symposium held on December 4, 2020.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Karyopharm Therapeutics Inc., Sanofi Genzyme, and Oncopeptides, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward hematologists and hematologists/oncologists interested in the treatment of patients with MM.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Implement novel therapeutic strategies for patients with relapsed/refractory (R/R) MM based on disease, treatment, and patient-related factors
  • Analyze the safety and efficacy data of novel and investigational therapies for the treatment of R/R MM
  • Explain the mechanisms of action of novel investigational therapies and the rationale supporting their utility in the treatment of R/R MM
  • Apply novel combination approaches to treat R/R MM

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

María-Victoria Mateos, MD, PhD
María-Victoria Mateos, MD, PhD
Associate Professor and Consulting Physician
Hematology Department
University Hospital of Salamanca
Salamanca, Spain

Disclosures: Consultant: Janssen Pharmaceutica, Celgene Corporation, Takeda Pharmaceutical Company, Amgen, Adaptive Biotechnologies, AbbVie, Glaxo Smith Kline, Hoffman-La Roche, Seattle Genetics, Pfizer, Regeneron Pharmaceuticals; Speakers Bureau: Janssen Pharmaceutica, Celgene Corporation, Takeda Pharmaceutical Company, Amgen, Adaptive Biotechnologies, AbbVie, GlaxoSmithKline.

Enrique M. Ocio MD, PhD
Enrique M. Ocio MD, PhD
Head of the Hematology Department
University Hospital Marqués de Valdecilla
University of Cantabria
Santander, Spain

Disclosures: Consultant: Bristol Myers Squibb, Sanofi, Glaxo Smith Kline, Janssen Pharmaceutica, Amgen, Secura Bio, Oncopeptides; Speakers Bureau: Takeda Pharmaceutical Company, Janssen Pharmaceutica; Other: Honoraria: Janssen Pharmaceutica, Asofarma, Sanofi, Bristol Myers Squibb, Amgen, Merck Sharp & Dohme, Takeda Pharmaceutical Company.

Ajai Chari, MD
Ajai Chari, MD
Professor of Medicine, Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Grant Research Support: Janssen Pharmaceutica, Celgene Corporation, Novartis Pharmaceuticals, Amgen, Pharmacyclics, Seattle Genetics, Millenium Pharmaceuticals/Takeda Pharmaceutical Company; Consultant: Janssen Pharmaceutica, Celgene Corporation, Novartis Pharmaceuticals, Amgen, Bristol Myers Squibb, Karyopharm, Sanofi Genzyme, Seattle Genetics, Oncopeptides, Takeda Pharmaceutical Company, Antengene, GlaxoSmithKline, Secura Bio.

Irene Ghobrial, MD
Irene Ghobrial, MD
Professor of Medicine, Harvard Medical School
Director of the Center for Prevention of Progression
Director of the Clinical Investigator Research Program
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Consultant: GlaxoSmithKline, Sanofi, Janssen Pharmaceutica, Takeda Pharmaceutical Company, Karyopharm, AbbVie, GNS Healthcare, Genentech, Adaptive Biotechnologies, Bristol Myers Squibb.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
3031
Filter By